nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—SLC47A1—Metformin—polycystic ovary syndrome	0.328	0.634	CbGbCtD
Imatinib—SLC22A2—Metformin—polycystic ovary syndrome	0.101	0.196	CbGbCtD
Imatinib—SLC22A1—Metformin—polycystic ovary syndrome	0.0881	0.17	CbGbCtD
Imatinib—Oedema aggravated—Metformin—polycystic ovary syndrome	0.0553	0.398	CcSEcCtD
Imatinib—Loose stools—Metformin—polycystic ovary syndrome	0.00346	0.0249	CcSEcCtD
Imatinib—Nail disorder—Metformin—polycystic ovary syndrome	0.00295	0.0212	CcSEcCtD
Imatinib—Heartburn—Metformin—polycystic ovary syndrome	0.00278	0.02	CcSEcCtD
Imatinib—DDR1—adrenal cortex—polycystic ovary syndrome	0.00265	0.0184	CbGeAlD
Imatinib—ABCA3—endometrium—polycystic ovary syndrome	0.00257	0.0178	CbGeAlD
Imatinib—Fungal infection—Metformin—polycystic ovary syndrome	0.00248	0.0178	CcSEcCtD
Imatinib—DDR1—endometrium—polycystic ovary syndrome	0.00237	0.0164	CbGeAlD
Imatinib—Rigors—Metformin—polycystic ovary syndrome	0.00234	0.0169	CcSEcCtD
Imatinib—CYP2C19—urine—polycystic ovary syndrome	0.00234	0.0162	CbGeAlD
Imatinib—ABCA3—pituitary gland—polycystic ovary syndrome	0.00232	0.0161	CbGeAlD
Imatinib—ABCA3—adipose tissue—polycystic ovary syndrome	0.00231	0.016	CbGeAlD
Imatinib—Contusion—Metformin—polycystic ovary syndrome	0.00219	0.0158	CcSEcCtD
Imatinib—DDR1—uterus—polycystic ovary syndrome	0.00218	0.0151	CbGeAlD
Imatinib—DDR1—pituitary gland—polycystic ovary syndrome	0.00214	0.0149	CbGeAlD
Imatinib—DDR1—adipose tissue—polycystic ovary syndrome	0.00213	0.0148	CbGeAlD
Imatinib—ABCA3—adrenal gland—polycystic ovary syndrome	0.00207	0.0144	CbGeAlD
Imatinib—ABCA3—female gonad—polycystic ovary syndrome	0.00193	0.0134	CbGeAlD
Imatinib—ABCA3—vagina—polycystic ovary syndrome	0.00192	0.0133	CbGeAlD
Imatinib—DDR1—adrenal gland—polycystic ovary syndrome	0.00191	0.0133	CbGeAlD
Imatinib—CYP1A2—urine—polycystic ovary syndrome	0.00191	0.0133	CbGeAlD
Imatinib—HIPK4—endocrine gland—polycystic ovary syndrome	0.00182	0.0126	CbGeAlD
Imatinib—CYP2C9—urine—polycystic ovary syndrome	0.00181	0.0126	CbGeAlD
Imatinib—DDR1—female gonad—polycystic ovary syndrome	0.00178	0.0124	CbGeAlD
Imatinib—DDR1—vagina—polycystic ovary syndrome	0.00177	0.0123	CbGeAlD
Imatinib—Lightheadedness—Metformin—polycystic ovary syndrome	0.00171	0.0123	CcSEcCtD
Imatinib—PIP4K2C—adrenal cortex—polycystic ovary syndrome	0.00164	0.0114	CbGeAlD
Imatinib—PDGFRA—embryo—polycystic ovary syndrome	0.00146	0.0101	CbGeAlD
Imatinib—PIP4K2C—endometrium—polycystic ovary syndrome	0.00146	0.0101	CbGeAlD
Imatinib—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.00142	0.0102	CcSEcCtD
Imatinib—Lethargy—Metformin—polycystic ovary syndrome	0.00142	0.0102	CcSEcCtD
Imatinib—ABL2—pituitary gland—polycystic ovary syndrome	0.0014	0.0097	CbGeAlD
Imatinib—ABL2—adipose tissue—polycystic ovary syndrome	0.00139	0.00966	CbGeAlD
Imatinib—Pain in extremity—Metformin—polycystic ovary syndrome	0.00139	0.00999	CcSEcCtD
Imatinib—CYP3A4—urine—polycystic ovary syndrome	0.00138	0.0096	CbGeAlD
Imatinib—Migraine—Metformin—polycystic ovary syndrome	0.00137	0.00983	CcSEcCtD
Imatinib—CYP2D6—urine—polycystic ovary syndrome	0.00136	0.00945	CbGeAlD
Imatinib—PIP4K2C—pituitary gland—polycystic ovary syndrome	0.00132	0.00917	CbGeAlD
Imatinib—PIP4K2C—adipose tissue—polycystic ovary syndrome	0.00132	0.00914	CbGeAlD
Imatinib—Dehydration—Metformin—polycystic ovary syndrome	0.00129	0.00929	CcSEcCtD
Imatinib—CSF1R—embryo—polycystic ovary syndrome	0.00129	0.00894	CbGeAlD
Imatinib—CA3—uterus—polycystic ovary syndrome	0.00129	0.00892	CbGeAlD
Imatinib—Abdominal pain upper—Metformin—polycystic ovary syndrome	0.00127	0.00912	CcSEcCtD
Imatinib—CA3—pituitary gland—polycystic ovary syndrome	0.00126	0.00876	CbGeAlD
Imatinib—CA3—adipose tissue—polycystic ovary syndrome	0.00126	0.00872	CbGeAlD
Imatinib—Breast disorder—Metformin—polycystic ovary syndrome	0.00126	0.00903	CcSEcCtD
Imatinib—Cramp muscle—Metformin—polycystic ovary syndrome	0.00125	0.009	CcSEcCtD
Imatinib—ABL2—adrenal gland—polycystic ovary syndrome	0.00125	0.00866	CbGeAlD
Imatinib—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00124	0.00893	CcSEcCtD
Imatinib—Abdominal distension—Metformin—polycystic ovary syndrome	0.00121	0.00869	CcSEcCtD
Imatinib—NQO2—adrenal cortex—polycystic ovary syndrome	0.0012	0.00834	CbGeAlD
Imatinib—Influenza—Metformin—polycystic ovary syndrome	0.0012	0.00863	CcSEcCtD
Imatinib—LCK—uterus—polycystic ovary syndrome	0.0012	0.00829	CbGeAlD
Imatinib—PIP4K2C—adrenal gland—polycystic ovary syndrome	0.00118	0.0082	CbGeAlD
Imatinib—Pancreatitis—Metformin—polycystic ovary syndrome	0.00118	0.00847	CcSEcCtD
Imatinib—Angina pectoris—Metformin—polycystic ovary syndrome	0.00117	0.00841	CcSEcCtD
Imatinib—Sweating increased—Metformin—polycystic ovary syndrome	0.00117	0.00841	CcSEcCtD
Imatinib—KIT—embryo—polycystic ovary syndrome	0.00117	0.00811	CbGeAlD
Imatinib—LCK—adipose tissue—polycystic ovary syndrome	0.00117	0.00811	CbGeAlD
Imatinib—ABL2—female gonad—polycystic ovary syndrome	0.00116	0.00808	CbGeAlD
Imatinib—ABL2—vagina—polycystic ovary syndrome	0.00116	0.00803	CbGeAlD
Imatinib—PDGFRB—embryo—polycystic ovary syndrome	0.00114	0.00793	CbGeAlD
Imatinib—Neutropenia—Metformin—polycystic ovary syndrome	0.00112	0.00807	CcSEcCtD
Imatinib—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.00112	0.00802	CcSEcCtD
Imatinib—PIP4K2C—female gonad—polycystic ovary syndrome	0.0011	0.00764	CbGeAlD
Imatinib—PIP4K2C—vagina—polycystic ovary syndrome	0.0011	0.0076	CbGeAlD
Imatinib—NQO2—endometrium—polycystic ovary syndrome	0.00107	0.00745	CbGeAlD
Imatinib—Infestation NOS—Metformin—polycystic ovary syndrome	0.00107	0.0077	CcSEcCtD
Imatinib—Infestation—Metformin—polycystic ovary syndrome	0.00107	0.0077	CcSEcCtD
Imatinib—CSF1R—adrenal cortex—polycystic ovary syndrome	0.00106	0.00732	CbGeAlD
Imatinib—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.00105	0.00755	CcSEcCtD
Imatinib—LCK—adrenal gland—polycystic ovary syndrome	0.00105	0.00728	CbGeAlD
Imatinib—CA3—vagina—polycystic ovary syndrome	0.00105	0.00725	CbGeAlD
Imatinib—PIP4K2C—endocrine gland—polycystic ovary syndrome	0.00102	0.00711	CbGeAlD
Imatinib—CA14—adrenal gland—polycystic ovary syndrome	0.00102	0.00711	CbGeAlD
Imatinib—ABL1—embryo—polycystic ovary syndrome	0.00102	0.00706	CbGeAlD
Imatinib—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.00101	0.00728	CcSEcCtD
Imatinib—NQO2—uterus—polycystic ovary syndrome	0.000989	0.00686	CbGeAlD
Imatinib—PDGFRA—uterus—polycystic ovary syndrome	0.000987	0.00684	CbGeAlD
Imatinib—CA3—endocrine gland—polycystic ovary syndrome	0.000978	0.00679	CbGeAlD
Imatinib—LCK—female gonad—polycystic ovary syndrome	0.000978	0.00678	CbGeAlD
Imatinib—LCK—vagina—polycystic ovary syndrome	0.000972	0.00674	CbGeAlD
Imatinib—NQO2—pituitary gland—polycystic ovary syndrome	0.000971	0.00674	CbGeAlD
Imatinib—NQO2—adipose tissue—polycystic ovary syndrome	0.000967	0.00671	CbGeAlD
Imatinib—PDGFRA—adipose tissue—polycystic ovary syndrome	0.000965	0.00669	CbGeAlD
Imatinib—SLC47A1—adrenal cortex—polycystic ovary syndrome	0.000964	0.00669	CbGeAlD
Imatinib—Rhinitis—Metformin—polycystic ovary syndrome	0.000964	0.00693	CcSEcCtD
Imatinib—Hepatitis—Metformin—polycystic ovary syndrome	0.000961	0.00691	CcSEcCtD
Imatinib—Hypoaesthesia—Metformin—polycystic ovary syndrome	0.000957	0.00688	CcSEcCtD
Imatinib—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000947	0.00681	CcSEcCtD
Imatinib—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000945	0.00679	CcSEcCtD
Imatinib—CSF1R—endometrium—polycystic ovary syndrome	0.000943	0.00654	CbGeAlD
Imatinib—CA9—endocrine gland—polycystic ovary syndrome	0.000937	0.0065	CbGeAlD
Imatinib—PDGFRB—adrenal cortex—polycystic ovary syndrome	0.000936	0.00649	CbGeAlD
Imatinib—Eye disorder—Metformin—polycystic ovary syndrome	0.000898	0.00646	CcSEcCtD
Imatinib—Flushing—Metformin—polycystic ovary syndrome	0.000892	0.00641	CcSEcCtD
Imatinib—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000892	0.00641	CcSEcCtD
Imatinib—Angiopathy—Metformin—polycystic ovary syndrome	0.000872	0.00627	CcSEcCtD
Imatinib—CYP3A7—endocrine gland—polycystic ovary syndrome	0.000869	0.00603	CbGeAlD
Imatinib—CSF1R—uterus—polycystic ovary syndrome	0.000869	0.00603	CbGeAlD
Imatinib—Immune system disorder—Metformin—polycystic ovary syndrome	0.000868	0.00624	CcSEcCtD
Imatinib—NQO2—adrenal gland—polycystic ovary syndrome	0.000868	0.00602	CbGeAlD
Imatinib—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000866	0.00623	CcSEcCtD
Imatinib—PDGFRA—adrenal gland—polycystic ovary syndrome	0.000866	0.006	CbGeAlD
Imatinib—Chills—Metformin—polycystic ovary syndrome	0.000863	0.0062	CcSEcCtD
Imatinib—SLC47A1—endometrium—polycystic ovary syndrome	0.000861	0.00597	CbGeAlD
Imatinib—KIT—endometrium—polycystic ovary syndrome	0.000856	0.00594	CbGeAlD
Imatinib—CSF1R—pituitary gland—polycystic ovary syndrome	0.000853	0.00592	CbGeAlD
Imatinib—CSF1R—adipose tissue—polycystic ovary syndrome	0.00085	0.00589	CbGeAlD
Imatinib—Erythema—Metformin—polycystic ovary syndrome	0.000837	0.00602	CcSEcCtD
Imatinib—Malnutrition—Metformin—polycystic ovary syndrome	0.000837	0.00602	CcSEcCtD
Imatinib—PDGFRB—endometrium—polycystic ovary syndrome	0.000836	0.0058	CbGeAlD
Imatinib—ABL1—adrenal cortex—polycystic ovary syndrome	0.000835	0.00579	CbGeAlD
Imatinib—Flatulence—Metformin—polycystic ovary syndrome	0.000825	0.00593	CcSEcCtD
Imatinib—Dysgeusia—Metformin—polycystic ovary syndrome	0.00082	0.00589	CcSEcCtD
Imatinib—NQO2—female gonad—polycystic ovary syndrome	0.000809	0.00561	CbGeAlD
Imatinib—PDGFRA—female gonad—polycystic ovary syndrome	0.000807	0.0056	CbGeAlD
Imatinib—Muscle spasms—Metformin—polycystic ovary syndrome	0.000805	0.00578	CcSEcCtD
Imatinib—NQO2—vagina—polycystic ovary syndrome	0.000804	0.00558	CbGeAlD
Imatinib—PDGFRA—vagina—polycystic ovary syndrome	0.000802	0.00556	CbGeAlD
Imatinib—SLC47A1—uterus—polycystic ovary syndrome	0.000793	0.0055	CbGeAlD
Imatinib—KIT—uterus—polycystic ovary syndrome	0.000789	0.00547	CbGeAlD
Imatinib—Vision blurred—Metformin—polycystic ovary syndrome	0.000789	0.00567	CcSEcCtD
Imatinib—ORM1—endometrium—polycystic ovary syndrome	0.000784	0.00544	CbGeAlD
Imatinib—Tremor—Metformin—polycystic ovary syndrome	0.000784	0.00564	CcSEcCtD
Imatinib—SLC47A1—pituitary gland—polycystic ovary syndrome	0.000779	0.0054	CbGeAlD
Imatinib—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000776	0.00558	CcSEcCtD
Imatinib—SLC47A1—adipose tissue—polycystic ovary syndrome	0.000776	0.00538	CbGeAlD
Imatinib—KIT—pituitary gland—polycystic ovary syndrome	0.000775	0.00537	CbGeAlD
Imatinib—KIT—adipose tissue—polycystic ovary syndrome	0.000772	0.00535	CbGeAlD
Imatinib—PDGFRB—uterus—polycystic ovary syndrome	0.00077	0.00534	CbGeAlD
Imatinib—CSF1R—adrenal gland—polycystic ovary syndrome	0.000762	0.00529	CbGeAlD
Imatinib—PDGFRB—pituitary gland—polycystic ovary syndrome	0.000757	0.00525	CbGeAlD
Imatinib—Malaise—Metformin—polycystic ovary syndrome	0.000755	0.00543	CcSEcCtD
Imatinib—PDGFRB—adipose tissue—polycystic ovary syndrome	0.000754	0.00523	CbGeAlD
Imatinib—NQO2—endocrine gland—polycystic ovary syndrome	0.000753	0.00522	CbGeAlD
Imatinib—PDGFRA—endocrine gland—polycystic ovary syndrome	0.000751	0.00521	CbGeAlD
Imatinib—Syncope—Metformin—polycystic ovary syndrome	0.00075	0.0054	CcSEcCtD
Imatinib—ABL1—endometrium—polycystic ovary syndrome	0.000745	0.00517	CbGeAlD
Imatinib—Palpitations—Metformin—polycystic ovary syndrome	0.00074	0.00532	CcSEcCtD
Imatinib—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000736	0.00529	CcSEcCtD
Imatinib—Hypertension—Metformin—polycystic ovary syndrome	0.000723	0.00519	CcSEcCtD
Imatinib—Chest pain—Metformin—polycystic ovary syndrome	0.000712	0.00512	CcSEcCtD
Imatinib—Myalgia—Metformin—polycystic ovary syndrome	0.000712	0.00512	CcSEcCtD
Imatinib—CSF1R—female gonad—polycystic ovary syndrome	0.000711	0.00493	CbGeAlD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000708	0.00509	CcSEcCtD
Imatinib—CSF1R—vagina—polycystic ovary syndrome	0.000706	0.0049	CbGeAlD
Imatinib—CA1—adipose tissue—polycystic ovary syndrome	0.000706	0.00489	CbGeAlD
Imatinib—Discomfort—Metformin—polycystic ovary syndrome	0.000704	0.00506	CcSEcCtD
Imatinib—SLC47A1—adrenal gland—polycystic ovary syndrome	0.000696	0.00483	CbGeAlD
Imatinib—CA2—embryo—polycystic ovary syndrome	0.000693	0.00481	CbGeAlD
Imatinib—CA12—endocrine gland—polycystic ovary syndrome	0.000693	0.00481	CbGeAlD
Imatinib—KIT—adrenal gland—polycystic ovary syndrome	0.000692	0.0048	CbGeAlD
Imatinib—ABL1—uterus—polycystic ovary syndrome	0.000687	0.00476	CbGeAlD
Imatinib—Oedema—Metformin—polycystic ovary syndrome	0.000683	0.00491	CcSEcCtD
Imatinib—Infection—Metformin—polycystic ovary syndrome	0.000679	0.00488	CcSEcCtD
Imatinib—PDGFRB—adrenal gland—polycystic ovary syndrome	0.000676	0.00469	CbGeAlD
Imatinib—ABL1—pituitary gland—polycystic ovary syndrome	0.000674	0.00468	CbGeAlD
Imatinib—Shock—Metformin—polycystic ovary syndrome	0.000672	0.00483	CcSEcCtD
Imatinib—ABL1—adipose tissue—polycystic ovary syndrome	0.000672	0.00466	CbGeAlD
Imatinib—Nervous system disorder—Metformin—polycystic ovary syndrome	0.00067	0.00482	CcSEcCtD
Imatinib—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000669	0.00481	CcSEcCtD
Imatinib—Skin disorder—Metformin—polycystic ovary syndrome	0.000663	0.00477	CcSEcCtD
Imatinib—CSF1R—endocrine gland—polycystic ovary syndrome	0.000661	0.00458	CbGeAlD
Imatinib—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.00066	0.00475	CcSEcCtD
Imatinib—Anorexia—Metformin—polycystic ovary syndrome	0.000651	0.00468	CcSEcCtD
Imatinib—SLC47A1—female gonad—polycystic ovary syndrome	0.000649	0.0045	CbGeAlD
Imatinib—SLC22A1—adipose tissue—polycystic ovary syndrome	0.000647	0.00449	CbGeAlD
Imatinib—KIT—female gonad—polycystic ovary syndrome	0.000645	0.00448	CbGeAlD
Imatinib—SLC47A1—vagina—polycystic ovary syndrome	0.000645	0.00447	CbGeAlD
Imatinib—KIT—vagina—polycystic ovary syndrome	0.000641	0.00445	CbGeAlD
Imatinib—Hypotension—Metformin—polycystic ovary syndrome	0.000638	0.00459	CcSEcCtD
Imatinib—PDGFRB—female gonad—polycystic ovary syndrome	0.00063	0.00437	CbGeAlD
Imatinib—PDGFRB—vagina—polycystic ovary syndrome	0.000626	0.00434	CbGeAlD
Imatinib—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000622	0.00447	CcSEcCtD
Imatinib—Paraesthesia—Metformin—polycystic ovary syndrome	0.000613	0.00441	CcSEcCtD
Imatinib—Dyspnoea—Metformin—polycystic ovary syndrome	0.000609	0.00438	CcSEcCtD
Imatinib—Somnolence—Metformin—polycystic ovary syndrome	0.000607	0.00437	CcSEcCtD
Imatinib—SLC47A1—endocrine gland—polycystic ovary syndrome	0.000604	0.00419	CbGeAlD
Imatinib—ABL1—adrenal gland—polycystic ovary syndrome	0.000602	0.00418	CbGeAlD
Imatinib—Dyspepsia—Metformin—polycystic ovary syndrome	0.000601	0.00432	CcSEcCtD
Imatinib—KIT—endocrine gland—polycystic ovary syndrome	0.0006	0.00416	CbGeAlD
Imatinib—Decreased appetite—Metformin—polycystic ovary syndrome	0.000594	0.00427	CcSEcCtD
Imatinib—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.00059	0.00424	CcSEcCtD
Imatinib—Fatigue—Metformin—polycystic ovary syndrome	0.000589	0.00423	CcSEcCtD
Imatinib—PDGFRB—endocrine gland—polycystic ovary syndrome	0.000586	0.00407	CbGeAlD
Imatinib—Constipation—Metformin—polycystic ovary syndrome	0.000584	0.0042	CcSEcCtD
Imatinib—CA2—adrenal cortex—polycystic ovary syndrome	0.000568	0.00394	CbGeAlD
Imatinib—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000563	0.00405	CcSEcCtD
Imatinib—ABL1—female gonad—polycystic ovary syndrome	0.000562	0.0039	CbGeAlD
Imatinib—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000559	0.00402	CcSEcCtD
Imatinib—ABL1—vagina—polycystic ovary syndrome	0.000558	0.00387	CbGeAlD
Imatinib—ALB—adrenal gland—polycystic ovary syndrome	0.000556	0.00386	CbGeAlD
Imatinib—ORM1—endocrine gland—polycystic ovary syndrome	0.00055	0.00381	CbGeAlD
Imatinib—CA1—endocrine gland—polycystic ovary syndrome	0.000549	0.00381	CbGeAlD
Imatinib—Urticaria—Metformin—polycystic ovary syndrome	0.000543	0.0039	CcSEcCtD
Imatinib—Abdominal pain—Metformin—polycystic ovary syndrome	0.00054	0.00388	CcSEcCtD
Imatinib—SLC22A1—vagina—polycystic ovary syndrome	0.000538	0.00373	CbGeAlD
Imatinib—ABCG2—adrenal cortex—polycystic ovary syndrome	0.000526	0.00365	CbGeAlD
Imatinib—ABL1—endocrine gland—polycystic ovary syndrome	0.000522	0.00362	CbGeAlD
Imatinib—SLC22A1—endocrine gland—polycystic ovary syndrome	0.000504	0.00349	CbGeAlD
Imatinib—Asthenia—Metformin—polycystic ovary syndrome	0.00049	0.00352	CcSEcCtD
Imatinib—Pruritus—Metformin—polycystic ovary syndrome	0.000483	0.00347	CcSEcCtD
Imatinib—ABCG2—endometrium—polycystic ovary syndrome	0.00047	0.00326	CbGeAlD
Imatinib—Diarrhoea—Metformin—polycystic ovary syndrome	0.000467	0.00336	CcSEcCtD
Imatinib—CA2—pituitary gland—polycystic ovary syndrome	0.000459	0.00319	CbGeAlD
Imatinib—CA2—adipose tissue—polycystic ovary syndrome	0.000457	0.00317	CbGeAlD
Imatinib—Dizziness—Metformin—polycystic ovary syndrome	0.000452	0.00325	CcSEcCtD
Imatinib—Vomiting—Metformin—polycystic ovary syndrome	0.000434	0.00312	CcSEcCtD
Imatinib—ABCG2—uterus—polycystic ovary syndrome	0.000433	0.003	CbGeAlD
Imatinib—Rash—Metformin—polycystic ovary syndrome	0.000431	0.0031	CcSEcCtD
Imatinib—Dermatitis—Metformin—polycystic ovary syndrome	0.00043	0.00309	CcSEcCtD
Imatinib—Headache—Metformin—polycystic ovary syndrome	0.000428	0.00308	CcSEcCtD
Imatinib—ABCG2—pituitary gland—polycystic ovary syndrome	0.000425	0.00295	CbGeAlD
Imatinib—ABCG2—adipose tissue—polycystic ovary syndrome	0.000424	0.00294	CbGeAlD
Imatinib—CYP2C19—vagina—polycystic ovary syndrome	0.000415	0.00288	CbGeAlD
Imatinib—CA2—adrenal gland—polycystic ovary syndrome	0.00041	0.00285	CbGeAlD
Imatinib—Nausea—Metformin—polycystic ovary syndrome	0.000406	0.00292	CcSEcCtD
Imatinib—CYP3A5—adipose tissue—polycystic ovary syndrome	0.000393	0.00273	CbGeAlD
Imatinib—PTGS1—endometrium—polycystic ovary syndrome	0.000392	0.00272	CbGeAlD
Imatinib—CYP2C19—endocrine gland—polycystic ovary syndrome	0.000388	0.00269	CbGeAlD
Imatinib—CA2—female gonad—polycystic ovary syndrome	0.000382	0.00265	CbGeAlD
Imatinib—CA2—vagina—polycystic ovary syndrome	0.00038	0.00264	CbGeAlD
Imatinib—ABCG2—adrenal gland—polycystic ovary syndrome	0.00038	0.00264	CbGeAlD
Imatinib—PTGS1—uterus—polycystic ovary syndrome	0.000361	0.00251	CbGeAlD
Imatinib—CA2—endocrine gland—polycystic ovary syndrome	0.000356	0.00247	CbGeAlD
Imatinib—PTGS1—pituitary gland—polycystic ovary syndrome	0.000355	0.00246	CbGeAlD
Imatinib—ABCG2—female gonad—polycystic ovary syndrome	0.000354	0.00246	CbGeAlD
Imatinib—PTGS1—adipose tissue—polycystic ovary syndrome	0.000353	0.00245	CbGeAlD
Imatinib—ABCG2—vagina—polycystic ovary syndrome	0.000352	0.00244	CbGeAlD
Imatinib—CYP3A5—female gonad—polycystic ovary syndrome	0.000329	0.00228	CbGeAlD
Imatinib—CYP3A5—vagina—polycystic ovary syndrome	0.000327	0.00227	CbGeAlD
Imatinib—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000317	0.0022	CbGeAlD
Imatinib—PTGS1—adrenal gland—polycystic ovary syndrome	0.000317	0.0022	CbGeAlD
Imatinib—ABCB1—embryo—polycystic ovary syndrome	0.000317	0.0022	CbGeAlD
Imatinib—CYP3A5—endocrine gland—polycystic ovary syndrome	0.000306	0.00212	CbGeAlD
Imatinib—CYP2C9—endocrine gland—polycystic ovary syndrome	0.000301	0.00209	CbGeAlD
Imatinib—PTGS1—female gonad—polycystic ovary syndrome	0.000295	0.00205	CbGeAlD
Imatinib—PTGS1—vagina—polycystic ovary syndrome	0.000294	0.00204	CbGeAlD
Imatinib—PTGS1—endocrine gland—polycystic ovary syndrome	0.000275	0.00191	CbGeAlD
Imatinib—ABCB1—adrenal cortex—polycystic ovary syndrome	0.00026	0.0018	CbGeAlD
Imatinib—CYP2D6—female gonad—polycystic ovary syndrome	0.000243	0.00168	CbGeAlD
Imatinib—ABCB1—endometrium—polycystic ovary syndrome	0.000232	0.00161	CbGeAlD
Imatinib—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000229	0.00159	CbGeAlD
Imatinib—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000226	0.00157	CbGeAlD
Imatinib—ABCB1—uterus—polycystic ovary syndrome	0.000214	0.00148	CbGeAlD
Imatinib—ABCB1—pituitary gland—polycystic ovary syndrome	0.00021	0.00145	CbGeAlD
Imatinib—ABCB1—adipose tissue—polycystic ovary syndrome	0.000209	0.00145	CbGeAlD
Imatinib—ABCB1—adrenal gland—polycystic ovary syndrome	0.000187	0.0013	CbGeAlD
Imatinib—ABCB1—female gonad—polycystic ovary syndrome	0.000175	0.00121	CbGeAlD
Imatinib—ABCB1—vagina—polycystic ovary syndrome	0.000174	0.0012	CbGeAlD
Imatinib—ABCB1—endocrine gland—polycystic ovary syndrome	0.000162	0.00113	CbGeAlD
Imatinib—ABCG2—Metabolism—NCOR1—polycystic ovary syndrome	7.64e-06	3.83e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—SULT2A1—polycystic ovary syndrome	7.64e-06	3.83e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	7.63e-06	3.83e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—NAMPT—polycystic ovary syndrome	7.63e-06	3.83e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	7.58e-06	3.81e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—SERPINE1—polycystic ovary syndrome	7.57e-06	3.8e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—NCOR1—polycystic ovary syndrome	7.57e-06	3.8e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKR1C1—polycystic ovary syndrome	7.57e-06	3.8e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—NCOR1—polycystic ovary syndrome	7.56e-06	3.8e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—BCL2—polycystic ovary syndrome	7.54e-06	3.79e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CYP11A1—polycystic ovary syndrome	7.53e-06	3.78e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	7.52e-06	3.77e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—SERPINE1—polycystic ovary syndrome	7.51e-06	3.77e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—LEP—polycystic ovary syndrome	7.5e-06	3.77e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HSD3B1—polycystic ovary syndrome	7.49e-06	3.76e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IRS1—polycystic ovary syndrome	7.48e-06	3.76e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	7.48e-06	3.76e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ADRB2—polycystic ovary syndrome	7.46e-06	3.75e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	7.45e-06	3.74e-05	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—IL6—polycystic ovary syndrome	7.44e-06	3.73e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	7.4e-06	3.72e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—GNAS—polycystic ovary syndrome	7.4e-06	3.71e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—RRM2—polycystic ovary syndrome	7.4e-06	3.71e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—IL6—polycystic ovary syndrome	7.39e-06	3.71e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—BCL2—polycystic ovary syndrome	7.35e-06	3.69e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—NCOR1—polycystic ovary syndrome	7.34e-06	3.68e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—CYP1A1—polycystic ovary syndrome	7.24e-06	3.64e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	7.22e-06	3.62e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—CYP1A1—polycystic ovary syndrome	7.18e-06	3.6e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—CYP1A1—polycystic ovary syndrome	7.17e-06	3.6e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—YAP1—polycystic ovary syndrome	7.13e-06	3.58e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	7.13e-06	3.58e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKR1C3—polycystic ovary syndrome	7.12e-06	3.57e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IRS1—polycystic ovary syndrome	7.07e-06	3.55e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—NCOR1—polycystic ovary syndrome	7.05e-06	3.54e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—TH—polycystic ovary syndrome	7.04e-06	3.53e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	7.02e-06	3.53e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	7.02e-06	3.52e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CYP17A1—polycystic ovary syndrome	7e-06	3.52e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—SULT2A1—polycystic ovary syndrome	6.96e-06	3.5e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	6.96e-06	3.49e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—CYP1A1—polycystic ovary syndrome	6.96e-06	3.49e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT2—polycystic ovary syndrome	6.93e-06	3.48e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—GNAS—polycystic ovary syndrome	6.92e-06	3.47e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IRS1—polycystic ovary syndrome	6.91e-06	3.47e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IRS2—polycystic ovary syndrome	6.91e-06	3.47e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—NAMPT—polycystic ovary syndrome	6.85e-06	3.44e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—SLC2A4—polycystic ovary syndrome	6.85e-06	3.44e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	6.83e-06	3.43e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—POMC—polycystic ovary syndrome	6.81e-06	3.42e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	6.81e-06	3.42e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	6.8e-06	3.41e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	6.8e-06	3.41e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—INS—polycystic ovary syndrome	6.77e-06	3.4e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP11A1—polycystic ovary syndrome	6.76e-06	3.4e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—LEP—polycystic ovary syndrome	6.76e-06	3.39e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—MTHFR—polycystic ovary syndrome	6.75e-06	3.39e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—RRM2—polycystic ovary syndrome	6.74e-06	3.39e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	6.72e-06	3.37e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—IL6—polycystic ovary syndrome	6.7e-06	3.36e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IRS1—polycystic ovary syndrome	6.69e-06	3.36e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—MTHFR—polycystic ovary syndrome	6.69e-06	3.36e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	6.68e-06	3.36e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—MTHFR—polycystic ovary syndrome	6.68e-06	3.35e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—CYP1A1—polycystic ovary syndrome	6.68e-06	3.35e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	6.68e-06	3.35e-05	CbGpPWpGaD
Imatinib—LCK—Disease—INS—polycystic ovary syndrome	6.62e-06	3.32e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	6.6e-06	3.31e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NCOR1—polycystic ovary syndrome	6.59e-06	3.31e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	6.56e-06	3.29e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IGF1—polycystic ovary syndrome	6.55e-06	3.29e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT2—polycystic ovary syndrome	6.54e-06	3.29e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—IL6—polycystic ovary syndrome	6.53e-06	3.28e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—YAP1—polycystic ovary syndrome	6.5e-06	3.26e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—MTHFR—polycystic ovary syndrome	6.49e-06	3.26e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NRG1—polycystic ovary syndrome	6.47e-06	3.25e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	6.46e-06	3.25e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—POMC—polycystic ovary syndrome	6.45e-06	3.24e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CYP19A1—polycystic ovary syndrome	6.44e-06	3.23e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—INS—polycystic ovary syndrome	6.41e-06	3.22e-05	CbGpPWpGaD
Imatinib—LCK—Disease—AKT2—polycystic ovary syndrome	6.4e-06	3.21e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKR1C3—polycystic ovary syndrome	6.39e-06	3.21e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	6.3e-06	3.16e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP17A1—polycystic ovary syndrome	6.29e-06	3.16e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NAMPT—polycystic ovary syndrome	6.24e-06	3.13e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	6.23e-06	3.13e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—MTHFR—polycystic ovary syndrome	6.23e-06	3.13e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	6.22e-06	3.12e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.22e-06	3.12e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	6.21e-06	3.12e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IGF1—polycystic ovary syndrome	6.2e-06	3.11e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT2—polycystic ovary syndrome	6.2e-06	3.11e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP11A1—polycystic ovary syndrome	6.17e-06	3.1e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	6.14e-06	3.08e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	6.12e-06	3.07e-05	CbGpPWpGaD
Imatinib—LCK—Disease—SERPINE1—polycystic ovary syndrome	6.08e-06	3.05e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—TH—polycystic ovary syndrome	6.06e-06	3.04e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	6.06e-06	3.04e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—BCL2—polycystic ovary syndrome	6.05e-06	3.04e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IRS1—polycystic ovary syndrome	6.03e-06	3.03e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	5.95e-06	2.99e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—SLC2A4—polycystic ovary syndrome	5.9e-06	2.96e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.89e-06	2.96e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	5.87e-06	2.95e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.84e-06	2.93e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKR1C3—polycystic ovary syndrome	5.82e-06	2.92e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—POMC—polycystic ovary syndrome	5.81e-06	2.92e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	5.78e-06	2.9e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	5.78e-06	2.9e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—INS—polycystic ovary syndrome	5.77e-06	2.9e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	5.76e-06	2.89e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	5.75e-06	2.88e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP17A1—polycystic ovary syndrome	5.73e-06	2.88e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IGF1—polycystic ovary syndrome	5.59e-06	2.8e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT2—polycystic ovary syndrome	5.58e-06	2.8e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	5.55e-06	2.79e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CYP19A1—polycystic ovary syndrome	5.54e-06	2.78e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IRS2—polycystic ovary syndrome	5.54e-06	2.78e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PPARG—polycystic ovary syndrome	5.47e-06	2.75e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	5.47e-06	2.75e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—TH—polycystic ovary syndrome	5.44e-06	2.73e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PPARG—polycystic ovary syndrome	5.43e-06	2.72e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—LEP—polycystic ovary syndrome	5.42e-06	2.72e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PPARG—polycystic ovary syndrome	5.42e-06	2.72e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—POMC—polycystic ovary syndrome	5.4e-06	2.71e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—IL6—polycystic ovary syndrome	5.38e-06	2.7e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—INS—polycystic ovary syndrome	5.37e-06	2.7e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—POMC—polycystic ovary syndrome	5.35e-06	2.69e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—POMC—polycystic ovary syndrome	5.34e-06	2.68e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	5.34e-06	2.68e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—INS—polycystic ovary syndrome	5.32e-06	2.67e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—INS—polycystic ovary syndrome	5.31e-06	2.67e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—TH—polycystic ovary syndrome	5.31e-06	2.67e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	5.31e-06	2.66e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SERPINE1—polycystic ovary syndrome	5.3e-06	2.66e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—SLC2A4—polycystic ovary syndrome	5.29e-06	2.66e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	5.27e-06	2.65e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	5.27e-06	2.65e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PPARG—polycystic ovary syndrome	5.26e-06	2.64e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	5.23e-06	2.63e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	5.19e-06	2.6e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—POMC—polycystic ovary syndrome	5.19e-06	2.6e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	5.17e-06	2.59e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—VEGFA—polycystic ovary syndrome	5.16e-06	2.59e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—INS—polycystic ovary syndrome	5.16e-06	2.59e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	5.15e-06	2.59e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PPARG—polycystic ovary syndrome	5.05e-06	2.53e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—TH—polycystic ovary syndrome	5e-06	2.51e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	4.99e-06	2.5e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—POMC—polycystic ovary syndrome	4.98e-06	2.5e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	4.98e-06	2.5e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP19A1—polycystic ovary syndrome	4.98e-06	2.5e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—TH—polycystic ovary syndrome	4.96e-06	2.49e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—INS—polycystic ovary syndrome	4.95e-06	2.49e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GNAS—polycystic ovary syndrome	4.95e-06	2.48e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	4.9e-06	2.46e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	4.87e-06	2.44e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	4.86e-06	2.44e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IRS1—polycystic ovary syndrome	4.84e-06	2.43e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	4.84e-06	2.43e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—SLC2A4—polycystic ovary syndrome	4.83e-06	2.42e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—NCOR1—polycystic ovary syndrome	4.71e-06	2.37e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—POMC—polycystic ovary syndrome	4.66e-06	2.34e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—INS—polycystic ovary syndrome	4.63e-06	2.33e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	4.59e-06	2.31e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	4.58e-06	2.3e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL6—polycystic ovary syndrome	4.58e-06	2.3e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP19A1—polycystic ovary syndrome	4.54e-06	2.28e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IGF1—polycystic ovary syndrome	4.48e-06	2.25e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT2—polycystic ovary syndrome	4.48e-06	2.25e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CYP1A1—polycystic ovary syndrome	4.47e-06	2.24e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	4.45e-06	2.23e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GNAS—polycystic ovary syndrome	4.44e-06	2.23e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	4.34e-06	2.18e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL6—polycystic ovary syndrome	4.33e-06	2.17e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	4.29e-06	2.15e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.28e-06	2.15e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SERPINE1—polycystic ovary syndrome	4.26e-06	2.14e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—TH—polycystic ovary syndrome	4.24e-06	2.13e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—NCOR1—polycystic ovary syndrome	4.23e-06	2.12e-05	CbGpPWpGaD
Imatinib—KIT—Disease—IL6—polycystic ovary syndrome	4.23e-06	2.12e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—MTHFR—polycystic ovary syndrome	4.17e-06	2.09e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	4.13e-06	2.07e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	4.12e-06	2.07e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	4.12e-06	2.07e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	4.09e-06	2.05e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	4.07e-06	2.04e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GNAS—polycystic ovary syndrome	4.05e-06	2.03e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.05e-06	2.03e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—polycystic ovary syndrome	4.04e-06	2.03e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP1A1—polycystic ovary syndrome	4.01e-06	2.01e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—polycystic ovary syndrome	4e-06	2.01e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	3.92e-06	1.97e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	3.91e-06	1.97e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—polycystic ovary syndrome	3.9e-06	1.96e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	3.89e-06	1.95e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	3.88e-06	1.95e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	3.87e-06	1.94e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—NCOR1—polycystic ovary syndrome	3.86e-06	1.94e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—INS—polycystic ovary syndrome	3.85e-06	1.93e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	3.84e-06	1.93e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—polycystic ovary syndrome	3.8e-06	1.91e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	3.78e-06	1.9e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—MTHFR—polycystic ovary syndrome	3.74e-06	1.88e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	3.69e-06	1.85e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP1A1—polycystic ovary syndrome	3.66e-06	1.84e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	3.65e-06	1.83e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—polycystic ovary syndrome	3.65e-06	1.83e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—polycystic ovary syndrome	3.6e-06	1.81e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	3.46e-06	1.74e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	3.44e-06	1.73e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—MTHFR—polycystic ovary syndrome	3.41e-06	1.71e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PPARG—polycystic ovary syndrome	3.38e-06	1.7e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—POMC—polycystic ovary syndrome	3.33e-06	1.67e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—INS—polycystic ovary syndrome	3.31e-06	1.66e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	3.3e-06	1.66e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	3.27e-06	1.64e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	3.18e-06	1.6e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—polycystic ovary syndrome	3.13e-06	1.57e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	3.13e-06	1.57e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PPARG—polycystic ovary syndrome	3.03e-06	1.52e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	2.99e-06	1.5e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—POMC—polycystic ovary syndrome	2.99e-06	1.5e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—INS—polycystic ovary syndrome	2.97e-06	1.49e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	2.96e-06	1.49e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—polycystic ovary syndrome	2.96e-06	1.49e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.93e-06	1.47e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—POMC—polycystic ovary syndrome	2.92e-06	1.47e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	2.91e-06	1.46e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—INS—polycystic ovary syndrome	2.9e-06	1.46e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—polycystic ovary syndrome	2.89e-06	1.45e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—polycystic ovary syndrome	2.8e-06	1.41e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	2.79e-06	1.4e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PPARG—polycystic ovary syndrome	2.76e-06	1.39e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	2.75e-06	1.38e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—INS—polycystic ovary syndrome	2.74e-06	1.37e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—POMC—polycystic ovary syndrome	2.73e-06	1.37e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—INS—polycystic ovary syndrome	2.71e-06	1.36e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	2.67e-06	1.34e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	2.54e-06	1.28e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—polycystic ovary syndrome	2.52e-06	1.27e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	2.41e-06	1.21e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	2.36e-06	1.19e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	2.33e-06	1.17e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—INS—polycystic ovary syndrome	2.32e-06	1.16e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	2.25e-06	1.13e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—polycystic ovary syndrome	2.02e-06	1.02e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.82e-06	9.15e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.8e-06	9.03e-06	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.79e-06	8.98e-06	CbGpPWpGaD
